Mer­ck and Ei­sai's Keytru­da/Lenvi­ma com­bo fails PhI­II tri­als for melanoma, col­orec­tal can­cer

Since 2018 — when Mer­ck and Ei­sai kicked off their col­lab­o­ra­tion to com­bine and test out Keytru­da and Lenvi­ma against mul­ti­ple can­cers — the two-drug com­bo has been ap­proved in ad­vanced re­nal cell car­ci­no­ma and cer­tain types of ad­vanced en­dome­tri­al car­ci­no­ma.

But as Mer­ck con­tin­ues on its quest to grow Keytru­da’s block­buster sta­tus ahead of a 2028 patent cliff, it hasn’t been all good news. Adding to the dis­ap­point­ment col­umn, the com­pa­nies re­port­ed two Phase III fails in un­re­sectable or metasta­t­ic melanoma and un­re­sectable and metasta­t­ic col­orec­tal can­cer last week in the LEAP clin­i­cal pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.